|
|
|
|
Vol. 60, Issue 2, 355-362, August 2001
Johns Hopkins University School of Medicine, Baltimore, Maryland (R.M.W.); and Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.L.M., J.K.L., L.O., M.W., M.K.D., P.L.P.)
| |
Abstract |
|---|
|
|
|---|
7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin [CPT-11 (irinotecan)] is a water-soluble camptothecin-derived prodrug that is activated by esterases to yield the potent topoisomerase I poison SN-38. We identified a rabbit liver carboxylesterase (CE) that was very efficient at CPT-11 metabolism; however, a human homolog that was more than 81% identical to this protein activated the drug poorly. Recently, two other human CEs have been isolated that are efficient in the conversion of CPT-11 to SN-38, yet both demonstrate little homology to the rabbit protein. To understand this phenomenon, we have characterized a series of esterases from human and rabbit, including several chimeric proteins, for their ability to metabolize CPT-11. Computer predictive modeling indicated that the ability of each enzyme to activate CPT-11 was dependent on the size of the entrance to the active site. Kinetic studies with a series of nitrophenyl and naphthyl esters confirmed these predictions, indicating that activation of CPT-11 by a CE is constrained by size-limited access of the drug to the active site catalytic amino acid residues.
| |
Introduction |
|---|
|
|
|---|
7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin
[CPT-11 (irinotecan)] is a prodrug that is activated by esterases to
generate 7-ethyl-10-hydroxycamptothecin (SN-38), a potent topoisomerase
I poison (Tanizawa et al., 1994
). Because CPT-11 has demonstrated
remarkable antitumor activity in human tumor xenograft models, this
drug is currently undergoing Phase II/III trials in both adults and
children (Houghton et al., 1993
, 1995
; Bugat et al., 1994
, 1995
;
Fujiwara et al., 1994
; Escudier et al., 1997
; Thompson et al., 1997a
,b
;
Furman et al., 1999
). Additionally, the FDA recently approved CPT-11 in
combination with 5-fluorouracil for front line treatment of colon cancer.
The enzymes involved in the metabolism of CPT-11 in humans have not
been fully characterized; hence the ability to tailor drug doses for
individual patients is difficult. This issue is complicated by the fact
that in rat and mouse model systems, more than 50% of CPT-11 is
converted to SN-38 (Morton et al., 2000
), whereas in humans, depending
on the dose and scheduling, as little as 1% of the drug is activated
(Rivory et al., 1997
). It is clear that either the levels of the
enzymes responsible for CPT-11 metabolism in humans are low or that
these proteins have significantly diverged in structure from rodent counterparts.
Recently, we isolated a rabbit liver carboxylesterase (CE) that could
efficiently convert CPT-11 to SN-38 (Potter et al., 1998a
). Searches of
the GenBank database indicated that a human homolog of this CE (hCE1)
with more than 81% amino acid identity had been identified previously.
However, expression of hCE1 in human tumor cells did not alter their
sensitivity to CPT-11, and in in vitro experiments, extracts derived
from these cells metabolized the drug poorly (Danks et al., 1999
). Very
recently two other human CEs, hCE2 and hiCE, have been demonstrated to
efficiently convert CPT-11 to SN-38 (Humerickhouse et al., 2000
; Khanna
et al., 2000
). These proteins are highly homologous to each other and
differ only in the 10 N-terminal residues. In contrast, the amino acid
sequences of human hiCE and hCE2 differ dramatically from that of the
rabbit CE (Khanna et al., 2000
).
Unfortunately, no three-dimensional structure of any mammalian CE is known. Hence, a structure-based understanding of the differences in the sequences of the various CEs and their effect on CPT-11 metabolism remains elusive. In an attempt to address why each CE exhibited different abilities to activate CPT-11 that were not predicted from the amino acid sequences, we used computer modeling studies to generate likely structures for rCE, hCE1, and hiCE. These modeling experiments suggested that the entrances to the active site in the CEs that cannot effectively metabolize CPT-11 are smaller than those in enzymes that can activate the drug. Kinetic data for activation of a series of substrates by the rCE and hCE1 were consistent with the computer models. Our combined modeling and experimental data indicate that steric constraints in the protein structures that limit the access of CPT-11 to the catalytic amino acids are probably responsible for the observed differences in prodrug activation.
| |
Materials and Methods |
|---|
|
|
|---|
CPT-11. CPT-11 was kindly provided by Dr. J. P. McGovren (Pharmacia, Peapack, NJ).
Transient Transfection of COS7 cells.
COS7 cells were
transfected with mammalian expression vectors as described previously
(Potter et al., 1998a
,b
). After 48 h, cells were harvested by
trypsinization and extracts were prepared by sonication in minimal
volumes of 50 mM HEPES, pH 7.4, on ice.
Molecular Modeling of Carboxylesterase Proteins.
Homology
models for hCE1, hiCE, and rCE were generated using the crystal
structure of Torpedo californica acetylcholinesterase (AChE)
containing the drug E2020 bound within the active site gorge (Kryger et
al., 1999
). Models were constructed using Modeller 4 software (Andrej
Sali, Rockefeller University, New York, NY) (Sali and Blundell, 1993
).
Sequences showing 30 to 50% identity/similarity have been shown to
give homology models that have 75 to 90% overlap of the
carbon
traces (within 3.5 Å) with the corresponding crystal structures
(Sanchez and Sali, 1998
). Hence, the homology models should be viewed
as low-resolution structures that may be used to aid in the
interpretation of our kinetic data. These and all subsequent
calculations reported here, unless otherwise noted, were performed
under the Linux 2.2 for x86 kernel.
0.43,
0.48, and
0.41,
respectively). The models were further minimized with a short (1 ps)
molecular dynamics run using the Molecular Modeling Toolkit (Hinsen,
2000Molecular Surface Calculations.
Analysis of the active site
gorges in the models was performed with the Molecular Modeling Toolkit
(Hinsen, 2000
) using a procedure modified from the work of McCammon and
colleagues (Tara et al., 1999
). Molecular surfaces were calculated for
each model using a probe radius that was incremented by 0.1 Å until
the surface no longer contained contributions from the active site
serine and histidine residues. As the active site serine and histidine residues are proposed to make initial contact with the ester bond to be
cleaved (Satoh and Hosokawa, 1998
), the largest probe radius that could
contact both residues was considered to provide the diameter of the
active site gorge.
Purified Carboxylesterases.
Pure rCE was prepared from
baculovirus-infected cell culture media as described previously (Morton
and Potter, 2000
). hCE1 was purified in an identical fashion. CE
activity for all enzymes was measured as described previously using
o-nitrophenyl acetate (o-NPA) as a substrate
(Beaufay et al., 1974
; Potter et al., 1998a
).
Kinetics of Nitrophenyl Esters Catalysis. Km, Kcat, and Vmax values were determined by monitoring conversion of nitrophenyl esters to nitrophenol spectrophotometrically at 420 nm. Substrates were dissolved in methanol and reactions performed in 50 mM HEPES, pH7.4. A minimum of eight concentrations of substrate was used, ranging from 10-fold less than the observed Km value to 5-fold greater. Data were collected over 45 s and reaction velocities determined from linear regressions of the initial data points. Kinetic parameters were determined from hyperbolic plots of reaction velocities versus substrate concentrations using the Prism software (GraphPad, San Diego, CA). r2 values were obtained from these curve fits.
Kinetics of Naphthyl Esters Catalysis. Km, Kcat, and Vmax values were determined as above except that substrates were dissolved in 2-methoxyethanol and the liberation of naphthol was measured at 230 nm. Linear regression of the initial data points was used to provide reaction velocities that were plotted against substrate concentration. Kinetic parameters were then calculated as described previously.
Kinetics of CPT-11 Metabolism.
To determine
Km, Kcat, and
Vmax values, rCE and hCE1 were incubated
with CPT-11 for 2 and 10 min, respectively, at 37°C in 200 µl of 50 mM HEPES, pH 7.4. The amounts of SN-38 in the reaction were quantitated
using high-performance liquid chromatography. Separation and detection
of CPT-11 and SN-38 were performed by high-performance liquid
chromatography as described previously (Guichard et al., 1998
). Data
were fitted to a one-site binding hyperbolic function using GraphPad
Prism software and Km and
Vmax values were determined from the
equation describing the curve fit. Because of the very high
Km value for hCE1, CPT-11 concentrations ranged from 1 to 250 µM for studies with this enzyme.
| |
Results |
|---|
|
|
|---|
Metabolism of CPT-11 by Chimeric Rabbit and hCE1 Proteins.
In
an attempt to identify domains responsible for CPT-11 recognition and
catalysis by CEs, we generated a series of chimeric proteins based upon
unique restriction sites present within identical regions of the rabbit
and hCE1 cDNAs. This produced three chimeric enzymes as indicated in
Fig. 1 and Table 1. To
determine the ability of these CEs to metabolize CPT-11, we ligated the
cDNAs into pCIneo and transiently transfected COS7 cells. Extracts were prepared by sonication of cells 48 h after transfection and their ability to hydrolyze o-NPA and CPT-11 were determined. As
can be seen, all proteins retained their ability to metabolize
o-NPA; however, RH2 activated CPT-11 with
approximately one tenth the activity of RH1 and RH3 (Table 1). RH2
contains amino acids residues 121 to 453 of hCE1, indicating that the
domains affecting CPT-11 metabolism are located within this region.
However, because this represents a significant proportion of the
enzyme, we thought it unlikely that we could identify specific residues
responsible for CPT-11 recognition and catalysis by mutagenesis
procedures. Hence, we adopted an alternative approach using computer
predictive modeling of the CEs.
|
|
Molecular Modeling of Carboxylesterase Proteins.
To perform
the computer homology studies, a template structure was required to
allow modeling of the CEs. To identify such a template, searches of the
protein database with the rCE amino acid sequence were performed. The
greatest homology was observed with T. californica AChE.
Subsequent alignments of the sequences of hCE1, hiCE, and rCE indicated
37.7%, 38.0%, and 32.5% identity, respectively, with AChE (Fig.
2) and 47.0%, 46.0%, and 40.5%
similarity, respectively, as computed by GAP (Devereux et al., 1984
).
As shown in Fig. 2, the homology of the sequences extends over the
length of the sequences; therefore, the global folding of the proteins is likely to be similar. This is also expected because the
/
-hydrolase tertiary fold is highly conserved among members of
this superfamily (Oakshott et al., 1999
). To generate models of the CE
proteins, the amino acids sequences were modeled upon the T. californica AChE crystal coordinates. The resulting molecular
surface representations of the initial homology models of hCE1,
hiCE, and rCE, after energy minimization with TINKER, are shown in Fig.
3. Overall, the models suggest that the
three proteins fit well into the folding pattern of T. californica AChE and consequently have similar overall molecular shape.
|
|
Analysis of Carboxylesterase Models.
As with AChE, the active
site Ser and His residues for rCE, hCE1, and hiCE lie at the bottom of
a negatively charged, ~22-Å-deep gorge in the interior of the
CEs. The gorge appears as the red "hole" in the molecular
surfaces shown in Fig. 3. The diameter of the distal end of the gorge,
where the active site residues are located, was calculated from the
molecular surfaces and indicated that all three enzymes can accommodate
similarly sized substrates (gorge diameters of 2.9 Å, 3.8 Å, and 3.2 Å for hCE1, hiCE, and rCE, respectively). These data are in good
agreement with previous molecular dynamics simulation studies of AChE,
in which the active site gorge fluctuates in size, ranging from 2.4 to
5.0 Å (Wlodek et al., 1997
; Tara et al., 1999
).
-carbon
positions in rCE (Phe87, Asn277, and Ile323), a crude estimate of the
active site opening for hiCE indicated it was similar to rCE (5-6 Å in diameter). Although this small difference in the gorge openings (4.2 Å vs. 5-6 Å) could be within the error of the homology model, the
estimated difference suggested that the sequence divergence between the rCE and hCE1 might result in a smaller entrance to the active site
gorge in hCE1 compared with rCE. Even a small change in gorge opening
or interior diameter could result in profound differences in the
esterase activity of the enzymes. For example, McCammon and colleagues
noted that for AcChE, the diameter of the active site gorge
substantially altered the rate of hydrolysis of substrates that differ
by as little as 0.4 Å in diameter (Zhou et al., 1998Kinetic Analysis of rCE and hCE1 Ester Metabolism.
Because the
computer-predicted models suggested that the entrance to the active
site gorge was narrower in hCE1 than rCE, we hypothesized that the
metabolism of bulky esters by the former protein may be less efficient
than by the rabbit enzyme. To determine whether this was the case, we
compared the ability of hCE1 and rCE to hydrolyze a series of
ortho- and para- isomers of nitrophenyl esters and esters of 1- and 2-naphthol. In nearly all cases, rCE was
more efficient at substrate metabolism than hCE1, as determined by
Kcat/Km values
(Table 2). A detailed example is included
with NPA and nitrophenyl butyrate (NPB). For both ortho-
substrates, the approximate molecular diameter of the compounds is 6.1 Å, whereas for the para- substrates, it is 4.4 Å. The
results of enzymatic cleavage of these substrates by hCE1 and rCE are
given in Table 2.
|
1
s
1, indicating a diminished ability to
accommodate substrate sizes of 4.4 Å or greater. rCE hydrolyzes
o-NPA and o-NPB at rates equivalent to those of
the hCE1. However, the smaller p-NPA and p-NPB
are hydrolyzed by rCE at a rate at least 10-fold greater than those for
the corresponding ortho- substrates. These data are in
agreement with the molecular modeling data, which suggest that
substrates with a diameter in the 3- to 4-Å range should be more
efficiently cleaved by rCE. Because the size of CPT-11 is within this
range, the NPA and NPB hydrolysis data suggest that substrate access to
the catalytic active sites is likely to be the primary reason for
differences in the ability of the CEs to hydrolyze this drug.
Influence of Ester Substituent on Enzyme Catalysis. We also examined the difference between rCE and hCE1 with a series of CE substrates having various group sizes on either side of the ester bond (Table 2). The majority of nitrophenyl esters interact with both rCE and hCE1 in a similar manner with regard to the Vmax. Acetate, propionate, and butyrate all have similar Vmax values for hCE1 (81-120 µmol/min/mg), indicating that esters containing 1-, 2-, and 3-carbon chains have approximately equivalent rates of catalysis. However, as described above, the para- esters were cleaved more efficiently by rCE. Excluding p-NPA, the Vmax values for rCE for all compounds ranged from 88 to 161 µmol/min/mg, indicating similar rates of cleavage for hCE1 and rCE (Table 2).
Both rCE and hCE1 demonstrated markedly reduced Vmax values for p-nitrophenyl valerate and p-nitrophenyl trimethylacetate. Hence, as the distance from the carboxyl group and bulkiness of the substrate increases, the rate of cleavage by CEs drops significantly. In agreement with the prediction that the active site gorge is larger in rCE, the decrease in Vmax with the valerate and methylacetate esters was only about 20% of that observed with the smaller substrates, whereas with hCE1, the Vmax values for these substrates were 2 orders of magnitude lower.Hydrophobic Constraints in Esterase-Mediated Catalysis. The Km values for the nitrophenyl esters probably reflect hydrophobic "steering" within the active site gorge as well as the actual size of the substrate. With the exception of the butyrate ester, the Km value for hCE1 mirrors the relative hydrophobicity of the p-nitrophenyl esters (trimethylacetate > valerate > propionate > acetate; Table 2). This observation suggests that, similar to AChE, these substrates interact with hydrophobic residues that line the active site gorges of both rCE and hCE1.
Interestingly, with rCE, the trimethylacetate ester has the lowest Km for the p- substituted compounds. However, the Km values for valerate, propionate, and acetate esters are approximately the same for rCE (Table 2). In both enzymes, p-nitrophenyl butyrate is out of order with regard to Km value and hydrophobicity, indicating that it binds poorly to hCE1 but very well to rCE. Clearly, there are physical interactions beyond simple hydrophobic binding for p-nitrophenyl butyrate, but the source of these interactions is not obvious from the models. Hydrophobic interactions by the butyrate moiety in 1-napthyl butyrate also follow the trend noted above for both hCE1 and rCE, with a lower Km value for 1-napthyl butyrate than 1-naphthyl acetate. hCE1 shows a decrease in Vmax value with 1-naphthyl butyrate versus 1-naphthyl acetate, whereas rCE demonstrates very small differences. In contrast, 2-napthyl acetate has a lower Km value for both hCE1 and rCE than 1-naphthylacetate, but the Vmax values drop considerably for this substrate with both enzymes (Table 2). The data suggest that the ability of both hCE1 and rCE to hydrolyze the substrates in Table 2 is controlled both by the steric properties of the substrates and their hydrophobic properties. Overall, rCE can hydrolyze bulkier substrates (including CPT-11) more efficiently than hCE1 because the entrance to the catalytic gorge of rCE is relatively large. However, when substrates are primarily involved with binding to the active site gorge via hydrophobic interactions, both enzymes are less efficient at hydrolysis. The observed properties determined experimentally are consistent with the models of hCE1 and rCE.| |
Discussion |
|---|
|
|
|---|
Computer-assisted searching of both nucleic acid and protein
databanks is used extensively to identify homologs of candidate genes.
In many cases, such searches yield genes demonstrating identical
functions in different species. In our studies with rCE, we identified
hCE1 as the closest human homolog of this protein and presumed,
therefore, that hCE1 was responsible for CPT-11 metabolism in humans.
Unexpectedly, hCE1 was found to be very inefficient at drug activation
even though it demonstrated greater than 81% identity and 86%
similarity with the rCE amino acid sequence (Danks et al., 1999
). The
lack of correlation between protein function and sequence initiated the
series of studies reported here to try to identify the amino acids
critical for CPT-11 recognition and activation by CEs. However, because
of the large size of these proteins (~560 amino acids), the use of
random mutagenesis studies was prohibitive. As an alternative, we
performed computer predictive modeling of the enzymes based upon the
T. californica AChE crystal structure (Kryger et al., 1999
)
and confirmed results of the modeling experiments with kinetic studies.
Cygler et al. (1993)
demonstrated that esterase structures could be
determined based upon their amino acid homology to two crystallized
proteins, T. californica AChE and Geotrichum
candidum lipase. However, these authors indicated that high amino
acid sequence homology was required for accurate structure prediction. More recently, the development of computer software, such as Modeler 4 (Andrei Sali, Rockefeller University, New York, NY; Sali and Blundell,
1993
), has allowed the prediction of protein structures that
demonstrate much lower homology (~30-50% identity; Xu et al., 1996
;
Sanchez and Sali, 1998
). Detailed analyses of these computer models
with actual structures determined from X-ray crystallographic studies
indicated the validity of this approach.
CEs can exist as multimers in cells; hence, determining the exact overall structure of the complex will require detailed X-ray crystallographic studies. However, without knowing the stoichiometry and detailed arrangement of the proteins in these aggregates, it is difficult to predict the overall structure of the enzyme complex.
Our computer models of hCE1 and rCE indicated that the entrance to the
active site was relatively narrow in the former enzyme and might
regulate access of substrates to the catalytic amino acids. Whereas
these modeling studies were underway, we and others isolated another
human CE that was proficient at CPT-11 activation (Humerickhouse et
al., 2000
; Khanna et al., 2000
). By comparing of molecular models of
all three proteins, we assessed possible structural reasons for the
inefficiency of hCE1 in converting CPT-11 to SN-38 versus the other two enzymes.
In the homology models, the active site serine and histidine residues
of all three CEs lie at the bottom of a ~22-Å gorge that is open to
the exterior of the protein. The piperidinopiperidine group that is
hydrolyzed from CPT-11 is, at its narrowest, 3.1 Å in diameter, and is
4.3 Å at its widest (see Fig. 4). Hence, only a molecule with this minimum diameter can pass through the gorge
to reach the active site residues of the CE. The active site gorge
diameter for all models is in the range of 3 to 4 Å. Hence, substrates
in this size range should be the most sensitive to differences in the
size of the active site gorge. Smaller substrates should fit equally
well into both active sites, whereas larger substrates should have
equally difficult access to the active site. In the models, we were
unable to clearly identify individual amino acids responsible for the
more compact gorge in hCE1 versus rCE. Rather, it is the global folding
of the enzyme, with slight displacement of most residues, which leads
to the inability of hCE1 to activate CPT-11. Our models of hCE1, hiCE,
and rCE suggested that the opening to the active site gorge was
slightly smaller in hCE1 than for hiCE and rCE, and that this steric
constraint impedes access to the active site residues and affects the
ability of the different CEs to hydrolyze CPT-11. Kinetic measurements on substrate metabolism by rCE and hCE1 (Table 2) agree with these
models.
|
Kroetz et al. (1993)
has demonstrated that inhibition of CE
glycosylation by tunicamycin reduces enzymatic activity of the human
CEs suggesting that addition of sugar residues is important for protein
function. Preliminary evidence demonstrates that the rabbit CE is
glycosylated at two Asn residues and that mutation of these residues
leads to reduced enzymatic activity (M. A. Espinosa, M. R. Redinbo and
P. M. Potter, unpublished observations). However, because hCE1
and rCE were both purified from baculovirus, they would be expected to
be glycosylated resulting in active enzyme. This was proved to be the
case because both proteins could metabolize simple CE substrates such
as o-NPA and o-NPB.
Other factors, such as electrostatic and hydrophobic interactions that
affect the cleavage of esters by CEs, may also be involved. However,
the CE protein family is highly promiscuous concerning the number of
structurally divergent compounds that they hydrolyze, to the extent
that classification based on phylogeny rather than substrate
specificity has been proposed (Satoh and Hosokawa, 1998
). In a study of
the ability of esterases in human whole blood to hydrolyze 80 different
ester-containing drugs, the overwhelming parameter that affected the
rate of hydrolysis was steric hindrance around the ester bond, with
lipophilicity and electronic parameters contributing much less to the
process (Buchwald and Bodor, 1999
). Our results are in agreement with
these previous reports; moreover, they suggest that tissue- or
species-specific activation of CPT-11 by CEs is controlled by the size
of the piperidinopiperidine ring system. Slight modifications to this
moiety of CPT-11 should allow optimization of hydrolysis by hCE1 and/or
hiCE, such that toxicities attributable to tissues-specific expression
of CEs may be minimized.
Ultimately, we would like to perform the detailed kinetic studies described in this manuscript with analogs of CPT-11, where the esterified bipiperidino function present at the 10-position of the molecule is replaced with other substituents. However, because of the unavailability of such reagents, we performed these analyses with commercially available substrates that demonstrated characteristics similar to CPT-11 (e.g., bulkiness, hydrophobicity). With an accurate model of protein structure, the design of novel CPT-11 analogs will be greatly simplified.
In conclusion, our modeling and experimental data indicate that the ability of CEs to metabolize CPT-11 is dependent on the access of the drug to the catalytic amino acids. This access is regulated by the size of the active site entrance. Therefore, hCE1 is less efficient at catalysis of bulky substrates than rCE and hiCE. Further elucidation of precise CPT-11-enzyme contacts in the active site gorge await detailed X-ray crystallographic studies of the CE proteins. However, we conclude that simply adjusting the size of the ester substituent cleaved by CEs could confer specificity of CPT-11 metabolism by esterases from different species or tissue types. This concept may be exploited for tissue-selective production of SN-38 from novel camptothecin analogs that differ only in the size of the esterified side chain.
| |
Acknowledgments |
|---|
We thank Dr. J. P. McGovren for the gift of CPT-11.
| |
Footnotes |
|---|
Received January 29, 2001; Accepted April 25, 2001
This work was supported in part by National Institutes of Health Grants CA76202, CA79763, the Cancer Center Core Grant CA21765, and the American Lebanese Syrian Associated Charities.
Dr. Philip M. Potter, Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105. E-mail: phil.potter{at}stjude.org
| |
Abbreviations |
|---|
CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan); SN-38, 7-ethyl-10-hydroxycamptothecin; CE, carboxylesterase; hCE human carboxylesterase, hiCE, human intestinal carboxylesterase; AChE, acetylcholinesterase; NPA, nitrophenyl acetate; rCE, rabbit liver carboxylesterase; NPB, nitrophenyl butyrate.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Takahashi, M. Katoh, T. Saitoh, M. Nakajima, and T. Yokoi Different Inhibitory Effects in Rat and Human Carboxylesterases Drug Metab. Dispos., May 1, 2009; 37(5): 956 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Williams, K. O. Jones, G. D. Ponsler, S. M. Lowery, E. J. Perkins, S. A. Wrighton, K. J. Ruterbories, M. Kazui, and N. A. Farid The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 Drug Metab. Dispos., July 1, 2008; 36(7): 1227 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Masaki, M. Taketani, and T. Imai FIRST-PASS HYDROLYSIS OF A PROPRANOLOL ESTER DERIVATIVE IN RAT SMALL INTESTINE Drug Metab. Dispos., March 1, 2006; 34(3): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. P. Yoon, J. L. Hyatt, C. L. Morton, R. E. Lee, P. M. Potter, and M. K. Danks Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application Mol. Cancer Ther., August 1, 2004; 3(8): 903 - 909. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Wadkins, J. L Hyatt, K. J. P. Yoon, C. L. Morton, R. E. Lee, K. Damodaran, P. Beroza, M. K. Danks, and P. M. Potter Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity Mol. Pharmacol., June 1, 2004; 65(6): 1336 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen Enzyme-Catalyzed Activation of Anticancer Prodrugs Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. P. Yoon, E. J. Krull, C. L. Morton, W. G. Bornmann, R. E. Lee, P. M. Potter, and M. K. Danks Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies Mol. Cancer Ther., November 1, 2003; 2(11): 1171 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kim, X.-y. Chu, S. Kim, C. J. Provoda, K.-D. Lee, and G. L. Amidon Identification of a Human Valacyclovirase: BIPHENYL HYDROLASE-LIKE PROTEIN AS VALACYCLOVIR HYDROLASE J. Biol. Chem., July 3, 2003; 278(28): 25348 - 25356. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xie, D. Yang, M. Wu, B. Xue, and B. Yan Mouse Liver and Kidney Carboxylesterase (M-LK) Rapidly Hydrolyzes Antitumor Prodrug Irinotecan and the N-Terminal Three Quarter Sequence Determines Substrate Selectivity Drug Metab. Dispos., January 1, 2003; 31(1): 21 - 27. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||